Fennec Pharmaceuticals Inc. (FENC)Healthcare | Biotechnology | Research Triangle Park, United States | NasdaqCM
10.72 USD
+0.01
(0.093%)
⇧
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:24 a.m. EDT
The investment thesis here rests entirely on the company's ability to execute its pipeline, as the balance sheet shows significant losses and negative equity returns. Fundamentally, the story is compelling: revenue growth is explosive at 85%, operating margins are healthy at nearly 10%, and the stock trades at a reasonable forward P/E of 11 given the growth profile. However, the lack of a dividend and the negative trailing EPS mean this is purely a capital appreciation play. The short-term outlook is cautiously constructive; while the statistical forecast model offers almost no directional guidance due to low reliability, the technical setup suggests a recovery from the 50-day average, and the heavy call positioning at lower strikes implies institutional support. The long-term rating is elevated because the business metrics—specifically the combination of high growth, positive operating cash flow, and a fortress-like current ratio—suggest the market is currently undervaluing the potential for a turnaround, despite the recent price weakness. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.104613 |
| MSTL | 0.114857 |
| AutoETS | 0.118570 |
| AutoARIMA | 0.118572 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.56 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.325 |
| Excess Kurtosis | -1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.847 |
| Market Cap | 375,919,968 |
| Forward P/E | 11.31 |
| Beta | 1.23 |
| Profit Margins | -5.49% |
| Website | https://www.fennecpharma.com |
As of Oct. 10, 2026, 7:24 a.m. EDT: Call volume is heavily concentrated in-the-money at the $7.5 strike, suggesting a floor or accumulation zone, while out-of-the-money interest is negligible. Put activity is dominated by deep out-of-the-money strikes with zero open interest, indicating a lack of hedging against a crash. The implied volatility skew is extreme, with ATM calls priced at 1.7 versus near-zero for puts, reflecting a speculative bias toward upside momentum rather than downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.29546833 |
| Address1 | 68 TW Alexander Drive |
| Address2 | PO Box 13628 |
| All Time High | 14.986 |
| All Time Low | 3.255 |
| Ask | 13.5 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 115,180 |
| Average Daily Volume3 Month | 188,184 |
| Average Volume | 188,184 |
| Average Volume10Days | 115,180 |
| Beta | 1.23 |
| Bid | 7.64 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 1.211 |
| City | Research Triangle Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.72 |
| Current Ratio | 5.85 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 10.83 |
| Day Low | 10.4214 |
| Display Name | Fennec Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,451,400 |
| Earnings Call Timestamp Start | 1,786,451,400 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -1,021,333 |
| Ebitda Margins | -0.01725 |
| Enterprise To Ebitda | -327.681 |
| Enterprise To Revenue | 5.651 |
| Enterprise Value | 334,670,944 |
| Eps Current Year | 0.322 |
| Eps Forward | 0.948 |
| Eps Trailing Twelve Months | -0.12 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.2154 |
| Fifty Day Average Change | -0.49539948 |
| Fifty Day Average Change Percent | -0.044171363 |
| Fifty Two Week Change Percent | 29.546833 |
| Fifty Two Week High | 13.25 |
| Fifty Two Week High Change | -2.5299997 |
| Fifty Two Week High Change Percent | -0.19094338 |
| Fifty Two Week Low | 5.65 |
| Fifty Two Week Low Change | 5.07 |
| Fifty Two Week Low Change Percent | 0.8973451 |
| Fifty Two Week Range | 5.65 - 13.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,505,482,200,000 |
| Float Shares | 19,877,118 |
| Forward Eps | 0.948 |
| Forward P E | 11.308017 |
| Free Cashflow | 1,070,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 35 |
| Fullday Change | 0.010000229 |
| Fullday Change Percent | 0.09337282 |
| Fullday Price | 10.72 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.93727 |
| Gross Profits | 55,506,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.14129 |
| Held Percent Institutions | 0.54236 |
| Implied Shares Outstanding | 35,067,159 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. |
| Long Name | Fennec Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 375,919,968 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1455350 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -3,250,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 381,157,455 |
| Number Of Analyst Opinions | 6 |
| Open | 10.68 |
| Operating Cashflow | -2,040,000 |
| Operating Margins | 0.09718 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.47 |
| Phone | 919 636 4530 |
| Previous Close | 10.71 |
| Price Eps Current Year | 33.291927 |
| Price Hint | 2 |
| Price To Book | 8.852189 |
| Price To Sales Trailing12 Months | 6.347748 |
| Profit Margins | -0.05488 |
| Quick Ratio | 5.205 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.0100002 |
| Regular Market Change Percent | 0.0933728 |
| Regular Market Day High | 10.83 |
| Regular Market Day Low | 10.4214 |
| Regular Market Day Range | 10.4214 - 10.83 |
| Regular Market Open | 10.68 |
| Regular Market Previous Close | 10.71 |
| Regular Market Price | 10.72 |
| Regular Market Time | 1,791,835,201 |
| Regular Market Volume | 90,128 |
| Return On Assets | -0.01165 |
| Return On Equity | -0.18583 |
| Revenue Growth | 0.852 |
| Revenue Per Share | 1.847 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 35,067,159 |
| Shares Percent Shares Out | 0.0146 |
| Shares Short | 513,287 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 520,659 |
| Short Name | Fennec Pharmaceuticals Inc. |
| Short Percent Of Float | 0.016900001 |
| Short Ratio | 2.45 |
| Source Interval | 15 |
| State | NC |
| Symbol | FENC |
| Target High Price | 20.0 |
| Target Low Price | 16.0 |
| Target Mean Price | 17.66667 |
| Target Median Price | 18.0 |
| Total Cash | 41,249,000 |
| Total Cash Per Share | 1.176 |
| Total Debt | 0 |
| Total Revenue | 59,221,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.0177 |
| Two Hundred Day Average Change | 1.7023001 |
| Two Hundred Day Average Change Percent | 0.1887732 |
| Type Disp | Equity |
| Volume | 90,128 |
| Website | https://www.fennecpharma.com |
| Zip | 27,709 |